肿瘤大小和位置对超声及CT引导经皮微波消融治疗肾细胞癌疗效与安全性的影响
该回顾性研究纳入56例患者共69个活检证实的肾肿瘤,评估肿瘤大小与中央位置对CEUS及CT引导经皮微波消融安全性和疗效的影响。所有病灶总体技术成功率为100%(首次技术成功率92.8%),局部肿瘤进展率5.8%,并发症率5.8%且均为轻微并发症。作者认为无论肾脏肿瘤测量评分和肿瘤位置如何,影像引导微波消融似乎都是安全有效的治疗方式。
要点
- 总体技术成功率为100%(首次技术成功率92.8%),局部肿瘤进展率5.8%,并发症率5.8%且无严重并发症。
- 需二次消融的5个病灶中位肿瘤大小4 cm,显著大于无需二次消融者(P=0.039),肾脏肿瘤测量评分无差异。
- 肾脏肿瘤测量评分与技术成功、复发或并发症率均无显著关联;消融前后eGFR无显著变化。
核心结论
- 影像引导微波消融似乎是不论肾脏肿瘤测量评分和肿瘤位置均安全有效的治疗方式,具有高技术成功率、低复发率和低并发症率。
研究设计与样本
- 经机构审查委员会批准的回顾性研究,纳入2013年1月至2017年3月在本机构接受微波消融的56例患者共69个活检证实的肾肿瘤。
- 评估内容包括人口学资料、肿瘤特征、手术方案及术后6个月内随访;主要结局为技术成功、局部肿瘤进展和并发症;采用Kaplan-Meier分析计算生存率。
诊断标准与关键数值
- 总体技术成功率为100%(首次技术成功率92.8%);中位肾脏肿瘤测量评分为8(范围4-11),中位肿瘤大小为2.5 cm(范围0.8-7)。
- 需二次消融的5个病灶中位肿瘤大小为4 cm,显著大于无需二次消融者(P=0.039),两组肾脏肿瘤测量评分相同。
- 局部肿瘤进展率为5.8%;复发肿瘤中最常见为透明细胞型(50%),其次为乳头状型(25%)。
- 并发症率为5.8%,均为轻微并发症(血肿和疼痛),无严重问题;肾脏肿瘤测量评分与技术成功、复发或并发症率均无显著关联。
- 中位随访11.9个月时,总体生存率和肿瘤特异性生存率分别为96.7%和100%;消融前后eGFR无显著变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the effect of size and central location of the tumor on safety and efficacy of percutaneous CEUS- and CT-guided MWA in biopsy-proven renal cell carcinomas (RCCs).
MATERIALS AND METHODS: In this IRB-approved retrospective study, 69 biopsy-proven renal tumors in 56 patients, who underwent MWA in our institution from January 2013 to March 2017, were evaluated. Data collection included demographics, tumor characteristics, procedural protocols, and follow-up visits within 6 months post procedure. Primary outcomes were assessed by technical success (TS), local tumor progression (LTP), and complications. The Kaplan-Meier analysis was used for survival rate.
RESULTS: Overall technical success was achieved for all 69 lesions (92.8% primary TS, 100% overall). Median nephrometry score was 8 (4-11) and median tumor size was 2.5 cm (0.8-7). Five lesions which required second ablation had significantly higher median tumor size 4 cm (P = 0.039) with the same nephrometry score. Renal function remained stable with no significant change in eGFR before or after ablation. The LTP rate was 5.8%. The most recurrent tumors were clear cell (50%) followed by papillary tumors (25%). The complication rate was 5.8% with minor complications (hematoma and pain) and no major issues. There was no significant association between nephrometry score and technical success, recurrence, or complication rates. Overall and tumor-specific survival rates were 96.7% and 100% at 11.9 months.
CONCLUSIONS: Image-guided MWA appears to be a safe and effective treatment regardless of nephrometry score and tumor location with high technical success, low recurrence, and complication rates.
引用
- Shakeri S, Afshari Mirak S, Mohammadian Bajgiran A, et al. The effect of tumor size and location on efficacy and safety of US- and CT- guided percutaneous microwave ablation in renal cell carcinomas. Abdom Radiol (NY). 2019. PMID: 30847565. doi:10.1007/s00261-019-01967-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。